申请人:Katzenellenbogen A. John
公开号:US20070021495A1
公开(公告)日:2007-01-25
Compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ER beta-selective and/or ER beta-specific ligands. Compounds herein include certain compounds which are ER beta-selective agonists. Compounds herein include ER beta-selective agonists which exhibit minimal agonist or antagonist effect on ER alpha. Compounds of the invention include those of formula I:
and any pharmaceutically acceptable salts, stereoisomers and prodrugs thereof wherein AR, R
1
, R
3
, and X
1
—X
4
are as defined hereinabove.
本发明涉及化合物、药学上可接受的盐、立体异构体和前药,它们是ER配体,特别是这些化合物是ER beta选择性和/或ER beta特异性配体。本文化合物包括某些ER beta选择性激动剂。本文化合物包括ER beta选择性激动剂,其在ER alpha上表现出最小的激动或拮抗作用。本发明的化合物包括式I的化合物:以及它们的任何药学上可接受的盐、立体异构体和前药,其中AR、R1、R3和X1-X4如上所定义。